CRIS Current Research Information System

MANCINI, MANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.449
NA - Nord America 4.294
EU - Europa 2.911
AF - Africa 270
SA - Sud America 193
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.128
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.244
VN - Vietnam 1.542
SG - Singapore 1.151
CN - Cina 904
GB - Regno Unito 667
IT - Italia 453
DE - Germania 393
SE - Svezia 336
HK - Hong Kong 274
FR - Francia 176
NL - Olanda 169
IN - India 162
RU - Federazione Russa 155
IE - Irlanda 135
UA - Ucraina 132
BR - Brasile 130
TG - Togo 88
JP - Giappone 82
ZA - Sudafrica 69
FI - Finlandia 60
KR - Corea 56
EE - Estonia 53
CI - Costa d'Avorio 52
JO - Giordania 40
CH - Svizzera 32
BG - Bulgaria 30
CA - Canada 30
TH - Thailandia 29
NG - Nigeria 25
BD - Bangladesh 24
ID - Indonesia 22
IR - Iran 22
AR - Argentina 21
BE - Belgio 21
IQ - Iraq 20
PL - Polonia 17
TW - Taiwan 17
EC - Ecuador 16
SA - Arabia Saudita 16
TR - Turchia 15
CZ - Repubblica Ceca 14
SC - Seychelles 14
ES - Italia 13
MX - Messico 13
PH - Filippine 13
GR - Grecia 10
PK - Pakistan 10
VE - Venezuela 10
AT - Austria 9
UZ - Uzbekistan 9
AU - Australia 7
RO - Romania 7
HR - Croazia 6
LB - Libano 6
LT - Lituania 6
MA - Marocco 6
MY - Malesia 6
NP - Nepal 6
CL - Cile 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
DZ - Algeria 3
GE - Georgia 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BY - Bielorussia 2
DK - Danimarca 2
HN - Honduras 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
MD - Moldavia 2
MU - Mauritius 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
CR - Costa Rica 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
GH - Ghana 1
GI - Gibilterra 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LY - Libia 1
MM - Myanmar 1
MR - Mauritania 1
Totale 12.121
Salva come PNG Salva come JPEG
Città #
Singapore 836
Southend 576
Ashburn 473
Chandler 469
Ho Chi Minh City 387
Fairfield 349
Hanoi 303
Hong Kong 260
San Jose 248
Wilmington 193
Seattle 191
Houston 171
Woodbridge 170
Dong Ket 160
Beijing 148
Princeton 138
Dublin 135
Cambridge 131
Ann Arbor 122
Hefei 102
Santa Clara 96
Bologna 89
Lomé 88
Boardman 84
Jacksonville 79
Tokyo 67
Nanjing 61
Lauterbourg 60
Westminster 58
New York 54
Abidjan 52
Los Angeles 52
Padova 52
Helsinki 47
Berlin 45
Da Nang 42
Seoul 42
Redmond 40
Frankfurt am Main 39
Milan 37
Amman 35
Redondo Beach 32
Haiphong 31
San Diego 31
Sofia 30
Shenyang 29
Jinan 28
Medford 28
Bern 27
Buffalo 24
Changsha 24
Saint Petersburg 24
Abeokuta 23
Biên Hòa 22
Ha Long 22
Munich 22
Falkenstein 21
Hebei 21
Brussels 20
Falls Church 20
Turin 20
Tianjin 19
Nanchang 18
Guangzhou 17
London 17
Dallas 16
Florence 16
Nuremberg 16
Zhengzhou 16
Bremen 15
Dearborn 15
Jiaxing 15
Johannesburg 14
Norwalk 14
Shanghai 14
Bengaluru 13
Mülheim 13
Thái Nguyên 13
Toronto 13
Atlanta 12
Council Bluffs 12
Jakarta 12
Phoenix 12
Rome 12
São Paulo 12
Taizhou 12
Bangkok 11
Can Tho 11
Des Moines 11
Orem 11
Xi'an 11
Baghdad 10
Bắc Ninh 10
Chicago 10
Hangzhou 10
Mountain View 10
Ninh Bình 10
Warsaw 10
Harbin 9
Hải Dương 9
Totale 7.781
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 656
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 275
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 272
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 265
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 241
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 226
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 226
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 219
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 219
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 212
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 211
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 201
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 194
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 188
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 186
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 185
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 183
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 180
C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. 177
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 176
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 172
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 171
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 171
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 170
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 169
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 167
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 166
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 165
Best practices in chronic myeloid leukemia monitoring and management 165
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 164
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities 163
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 160
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 159
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 158
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 158
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy 158
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 157
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 157
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 155
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. 153
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 153
mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein 152
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 151
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 151
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. 150
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 149
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 145
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 144
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 144
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 144
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 141
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 141
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 141
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 138
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 138
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 137
A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias 136
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort? 132
RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia 131
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 126
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 126
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 124
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 123
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 120
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 119
Systemic mastocytosis: Molecular landscape and implications for treatment 119
Present and future of molecular monitoring in chronic myeloid leukaemia. 118
Idetification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. 117
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 117
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 113
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia 108
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 97
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 94
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability 28
A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib 2
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3 sigma case. 2
Totale 12.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.528
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.528
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021394 0 0 0 0 0 0 0 0 0 41 49 304
2021/20221.273 138 25 78 83 117 77 28 87 57 85 250 248
2022/20231.640 185 263 88 197 119 128 59 73 281 41 133 73
2023/2024449 20 79 27 63 37 100 22 29 14 21 16 21
2024/20251.685 47 273 152 118 201 71 137 79 34 216 83 274
2025/20264.158 400 722 303 282 516 208 338 163 951 275 0 0
Totale 12.321